VEGFR2-Hemmer bei metastasiertem Brustkrebs ohne Zusatznutzen

Info Onkologie(2015)

Cited 0|Views3
No score
Key words
Mammakarzinom, Ramucirumab, Erstlinientherapie, ROSE/TRIO-12, Phase-III-Studies, Biomarker
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined